Oragenics (OGEN) announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio. The partnership aims to utilize advanced AI modeling to identify optimal receptor binding profiles for novel compounds acquired by Oragenics in 2023. Receptor.AI will apply its proprietary computational models to analyze Oragenics’ molecule structures to inform laboratory testing strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN: